Aurigene Pharmaceutical Services, a Dr Reddy’s Laboratories company, has opened its novel biologics facility spread across 70,000 sqft in Hyderabad, India.
The facility is designed to serve customers with process & analytical development and small scale manufacturing of antibodies and other recombinant proteins for preclinical and early phase clinical requirements.
The process and analytical development laboratories are now operational, while the commissioning of manufacturing capacity will be completed later in 2024.
Producing recombinant proteins end-to-end
The new facility is complementary to the company’s current discovery capabilities and infrastructure, which primarily focuses on recombinant proteins including mAbs, bi- and multi-specifics, immune-fusion molecules, antibody drug conjugates and other complex proteins.
Aurigene’s comprehensive end-to-end service offering now delivers solutions from discovery through to large-scale commercial manufacturing from three proximally located campuses thus ensuring delivery from “concept to commercial”.
The newly opened Genome Valley facility will deliver robust, compliant and economically viable cell lines and process development solutions.
The opening of this latest facility is one of multiple strategic initiatives that Aurigene is implementing to support growth in both the small molecule and biologics spaces.
Aurigene’s Global Commercial Head of Biologics, Dr Roger Lias commented: “There are few global CDMOs that can support customers “end-to-end” from discovery services to large scale commercial manufacture of both Drug Substance and Drug Product. Our new facility further strengthens Aurigene’s capability to serve start-ups through to global multinationals.”